<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966615</url>
  </required_header>
  <id_info>
    <org_study_id>Balance BCM</org_study_id>
    <nct_id>NCT00966615</nct_id>
  </id_info>
  <brief_title>The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition</brief_title>
  <official_title>The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition - A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic utilization of bio-incompatible peritoneal dialysis (PD) solution has been implicated
      as a cause of progressive loss of peritoneal permeability and recurrent fluid overload in PD
      patients. Previous studies show that PD solution with neutral pH and low GDP resulted in a
      superior profile of PD effluent mesothelial cell marker and a lower degree of systemic
      inflammation as compared to conventional PD solution. The investigators propose a prospective
      randomized control study to compare the arterial stiffness, nutrition and body fluid status
      between PD patients treated with conventional solution and those with neutral pH low GDP
      solution. The investigators plan to study 100 new PD patients. They will be randomized to be
      treated with neutral pH low GDP solution or conventional solution. All patients will be
      followed for 52 weeks. In addition to routine clinical measurements, the investigators will
      measure their body water composition by bioimpedance spectroscopic method, arterial pulse
      wave velocity by pressure transduction method, as well as radiographic parameters of
      intravascular volume status, based on the routine chest radiograph. The study would help to
      define the clinical benefit of biocompatible PD solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (see above)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body composition</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial pulse wave velocity</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>nutritional and adequacy indices</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peritoneal transport characteristics</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>residual renal function</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peritonitis-free survival, actuarial and technique survival</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Renal Failure</condition>
  <condition>ESRD</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Balance group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional PD solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>double-chamber bag Stay-Safe Balance system</intervention_name>
    <description>2-L exchange; three times a day</description>
    <arm_group_label>Balance group</arm_group_label>
    <other_name>Stay-Safe Balance system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>glucose-based dialysis solution</intervention_name>
    <description>2-L exchange; three times a day</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Stay-Safe, Fresenius</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  new adult continuous ambulatory peritoneal dialysis (CAPD) patients, both diabetic and
             non-diabetic

        Exclusion Criteria:

          -  unlikely to survive, planned to have elective living-related kidney transplant, or
             transfer to other renal center within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheuk Chun Szeto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip KT Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Prince of Wales Hospital, Shatin, Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine &amp; Therapeutics, Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Cheuk-Chun SZETO</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>malnutrition</keyword>
  <keyword>fluid status</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

